| Comparing the Brief Assessment of Cognitive Health and Montreal Cognitive Assessment: Test-retest reliability and sensitivity to cognitive change in older adults DP Floden, K Curran, O Hogue, K Krishnan, SA Saxena, C Sonneborn, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| A passive electronic medical record-based cognitive risk calculator predicts neuropsychological performance in older adults. SA Saxena, O Hogue, MB Rothberg, AD Misra-Hebert, AP Milinovich, ... Alzheimer's Association International Conference, 2024 | | 2024 |
| Association of patient-reported cognitive impairment with quality of life and employment in multiple sclerosis S Lancia, RA Marrie, G Cutter, RJ Fox, A Salter Multiple Sclerosis and Related Disorders 87, 105675, 2024 | | 2024 |
| Symptom Comparison after Infections Among People with MS A Salter, S Lancia, GR Cutter, A Novak, RA Marrie, RJ Fox 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers, 2024 | | 2024 |
| Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis RJ Fox, BAC Cree, J de Sèze, R Gold, HP Hartung, D Jeffery, L Kappos, ... Neurology 102 (9), e209357, 2024 | 2 | 2024 |
| Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial RJ Fox, H Wiendl, C Wolf, N De Stefano, J Sellner, V Gryb, K Rejdak, ... Neurology: Neuroimmunology & Neuroinflammation 11 (3), e200208, 2024 | 1 | 2024 |
| Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges J Chataway, T Williams, V Li, RA Marrie, D Ontaneda, RJ Fox The Lancet Neurology 23 (3), 277-301, 2024 | 7 | 2024 |
| Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis K Nakamura, B Thoomukuntla, J Bena, JA Cohen, RJ Fox, D Ontaneda Multiple Sclerosis Journal 30 (3), 369-380, 2024 | 2 | 2024 |
| Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA AK Carlson, RJ Fox Neurologic Clinics 42 (1), 39-54, 2024 | 2 | 2024 |
| Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis DC Ladakis, MI Reyes-Mantilla, SP Gadani, JW Mace, ... Multiple Sclerosis Journal 30 (1), 35-43, 2024 | | 2024 |
| Characterizing multiple sclerosis disease progression using a combined structural and functional connectivity metric PK Bhattacharyya, RJ Fox, KE Sakaie, J Bena, T Harvey, P Raska, J Lin, ... Magnetic Resonance Imaging 103, 185-191, 2023 | | 2023 |
| Design of the Phase 2 FUSION Trial of Reversible Non-covalent BTK Inhibitor BIIB091 in Participants with Relapsing Forms of Multiple Sclerosis JA Torres, RJ Fox, DL Arnold, A Cross, A Bar-Or, G Giovannoni, I Tagge, ... MULTIPLE SCLEROSIS JOURNAL 29, 934-935, 2023 | | 2023 |
| Evaluating GFAP and Contactin-1 as Treatment Response Biomarkers in Progressive MS RJ Fox, T Harvey, SI Veld, A Plaga, C Teunissen MULTIPLE SCLEROSIS JOURNAL 29, 563-563, 2023 | | 2023 |
| DISCOntinuation of disease-modifying therapies in multiple sclerosis (DISCOMS): primary results of the extension trial J Corboy, E Engebretson, G Cutter, RJ Fox, I Kister, A Miller, C Morgan, ... MULTIPLE SCLEROSIS JOURNAL 29, 356-357, 2023 | 1 | 2023 |
| Evaluating the relation of NfL, GFAP and Contactin-1 in serum and CSF with clinical and MRI measures in Progressive MS RJ Fox, T Harvey, S In't Veld, P Benkert, A Plaga, J Kuhle, C Teunissen MULTIPLE SCLEROSIS JOURNAL 29, 45-45, 2023 | | 2023 |
| MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results D Reich, A Traboulsee, J Oh, RJ Fox, S Syed, D Dukovic, T Turner, ... MULTIPLE SCLEROSIS JOURNAL 29, 592-592, 2023 | | 2023 |
| Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPHASIS Study R Fox, C Wolf, A Muehler, M Ondrus, V Sciacca, H Kohlhof, D Vitt MULTIPLE SCLEROSIS JOURNAL 29, 886-886, 2023 | | 2023 |
| Highly Sensitive Proteomic Immunoassays to Identify Novel Biomarkers for Multiple Sclerosis Disease Progression in Ibudilast Treated Patients S In't Veld, E Willemse, M Gouda, M Koel-simmelink, RJ Fox, C Teunissen MULTIPLE SCLEROSIS JOURNAL 29, 884-884, 2023 | | 2023 |
| Baseline Characteristics in the Tolebrutinib Phase 3 Non-Relapsing Secondary Progressive Multiple Sclerosis (nrSPMS) HERCULES Clinical Trial RJ Fox, A Bar-Or, A Traboulsee, C Oreja-Guevara, G Giovannoni, ... MULTIPLE SCLEROSIS JOURNAL 29, 938-939, 2023 | | 2023 |
| Effect of natalizumab on cortical gray matter and thalamic volume loss versus a historical placebo in early relapsing remitting multiple sclerosis K Nakamura, J Perumal, R Balabanov, L Balcer, S Galetta, Z Sun, H Li, ... MULTIPLE SCLEROSIS JOURNAL 29, 375-376, 2023 | | 2023 |
Amit Bar-OrProfessor, University of Pennsylvania在 pennmedicine.upenn.edu 的电子邮件经过验证
